Genetically modified natural killer cells for CD70-directed cancer immunotherapy
US12012458B2 · kind B2 · utility
1Cited by
4References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 10, 2021 |
| Grant date | Jun 18, 2024 |
| Priority date | — |
| Expiry date | Feb 5, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/80
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.